Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Completed
- Conditions
- clear cell renal cell carcinomakidney cancer10038364
- Registration Number
- NL-OMON35791
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Age 18 years or older
2. Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases
3. Written informed consent
Exclusion Criteria
1. Use of L-dopa or SSRI
2. Patients with a second primary malignancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear<br /><br>cell renal cell carcinoma and healthy controls, and patients with low grade<br /><br>neuroendocrine tumours and healthy controls.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear<br /><br>cell renal cell carcinoma and low grade neuroendocrine tumours before start of<br /><br>a treatment cycle and during a treatment cycle.</p><br>